Sight Sciences Q1 revenue up 13% to $19.7M; raises FY 2026 guidance; Alcon damages $55.4M

Sight Sciences, Inc.

2026-Q1 EPS reported -$0.24 revenue$19,698,000

Q1 revenue $19.7M (+13% YoY); net loss $13.0M ($0.24 loss per share) vs $14.2M loss in prior year.
Interventional Dry Eye revenue $1.4M (+244% YoY, +87% QoQ); Glaucoma revenue $18.3M (+7% YoY).
FY 2026 revenue guidance raised to $83M-$89M from $82M-$88M; adj. opex reaffirmed $93M-$96M.
Final Alcon judgment: $55.4M past damages + 10% ongoing royalty for Hydrus patent infringement (subject to appeal).

item 2.02 item 7.01 item 9.01

Key facts

Extracted from this filing and checked against the source text.

Earnings Releases SEC 8-K Item 2.02 confidence 0.9

Sight Sciences, Inc. reported the first quarter ended March 31, 2026 results: revenue $19.7 million, net income Net loss was $13.0 million, EPS loss of $0.24 per share. Guidance raised.

Period: the first quarter ended March 31, 2026
Revenue: $19.7 million
Net income: Net loss was $13.0 million
EPS: loss of $0.24 per share
Guidance: raised
Result: reported results

Exact text from the filing

results for the first quarter ended March 31, 2026 and raised its revenue guidance for full year 2026. Recent Financial and Business Highlights • Generated total revenue of $19.7 million in the first quarter of 2026, an increase of 13% compared to the same period in the prior year. • Drove Interventional Glaucoma revenue growth of 7% in the first quarter of 2026,

View on SEC.gov

44 earnings releases filed in the last 30 days. Browse all earnings releases →

Sight Sciences, Inc. filing history →

Source: SEC EDGAR

accession 0001193125-26-208959

view filing index on sec.gov

view primary document

Machine-readable: JSON · Markdown · Plain text

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.